Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome.
Stress and the risk of multiple sclerosis.
Fingolimod modulates microglial activation to augment markers of remyelination.
Control of experimental autoimmune uveoretinitis by low dose T cell vaccination.
Suppression of Murine Experimental Autoimmune Optic Neuritis by Mature Dendritic Cells Transfected with Calcitonin Gene-Related Peptide Gene.
Combined central and peripheral demyelination: Clinical features, diagnostic findings, and treatment.
Reduction of inflammation and preservation of neurological function by anti-CD52 therapy in murine experimental autoimmune encephalomyelitis.
Evaluating more naturalistic outcome measures: A 1-year smartphone study in multiple sclerosis.
Asymptomatic lung disease caused by Mycobacterium kansasii as an opportunistic infection in a patient treated with natalizumab for relapsing-remitting multiple sclerosis.
Effect of met-enkephalin on chromosomal aberrations in the lymphocytes of the peripheral blood of patients with multiple sclerosis.
Pregnancy outcomes in female patients and partners of male patients in the teriflunomide clinical development program.
3D models of human ERα and ERβ complexed with coumestrol.
[The Sjögren's syndrome and multiple sclerosis: similarity and differences.]
New data show positive results from Phase 4 study of Avonex Pen for treatment of RRMS patients
Amyloid precursor protein at node of Ranvier modulates nodal formation.
MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial
The neutralizing antibody GNbAC1 abrogates HERV-W envelope protein-mediated oligodendroglial maturation blockade.
Accentia Biopharmaceuticals Conducts Investigator Meeting in Preparation for New Multiple Sclerosis Drug Study for Cyrevia™
Circulating microRNAs as biomarkers for disease staging in multiple sclerosis.
Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort study.
Severe anemia in a patient with multiple sclerosis treated with natalizumab.
RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis.
English Court of Appeal finds in favor of Teva on Copaxone(R) patent litigation and upholds validity of Copaxone patent until May 2015
Multiple sclerosis susceptibility genes: associations with relapse severity and recovery.
The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group.

Pages